Literature DB >> 23453887

Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease.

Giammarco Mocci1, Manuela Marzo, Alfredo Papa, Alessandro Armuzzi, Luisa Guidi.   

Abstract

The clinical introduction of tumour necrosis factor (TNF) inhibitors has deeply changed the treatment of inflammatory bowel diseases (IBD). It has demonstrated impressive efficacy as compared to alternative treatments, allowing for the chance to achieve near-remission and long-term improvement in function and quality of life and to alter the natural history of Crohn's disease (CD) and ulcerative colitis (UC). As a consequence of longer follow-up periods the number of side effects which may be attributed to treatment with biologics is growing significantly. Cutaneous reactions are among the most common adverse reactions. These complications include injection site reactions, cutaneous infections, immune-mediated complications such as psoriasis and lupus-like syndrome and rarely skin cancers. We review the recent literature and draw attention to dermatological side effects of anti-TNF therapy of inflammatory bowel disease.
Copyright © 2013 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-TNF; IBD; Skin manifestations

Mesh:

Substances:

Year:  2013        PMID: 23453887     DOI: 10.1016/j.crohns.2013.01.009

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  31 in total

1.  Symmetrical drug-related intertriginous and flexural exanthema (Baboon syndrome) associated with infliximab.

Authors:  Isil Bulur; Havva Ozge Keseroglu; Zeynep Nurhan Saracoglu; Müzeyyen Gönül
Journal:  J Dermatol Case Rep       Date:  2015-03-31

2.  A study investigating the association of dermatological and infusion reactions to infliximab and infliximab trough levels.

Authors:  Vivian Huang; Neil Dhami; Darryl Fedorak; Connie Prosser; Carol Shalapay; Karen I Kroeker; Brendan P Halloran; Levinus A Dieleman; Richard N Fedorak
Journal:  Can J Gastroenterol Hepatol       Date:  2015 Jan-Feb

Review 3.  A Practical Guide to the Safety and Monitoring of New IBD Therapies.

Authors:  Benjamin Click; Miguel Regueiro
Journal:  Inflamm Bowel Dis       Date:  2019-04-11       Impact factor: 5.325

Review 4.  Review.

Authors:  Vikas Pabby; Robert Burakoff
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-08

5.  Orally administered emu oil attenuates disease in a mouse model of Crohn's-like colitis.

Authors:  Chloe J Mitchell; Gordon S Howarth; Lauren C Chartier; Debbie Trinder; Ian C Lawrance; Li San Huang; Suzanne Mashtoub
Journal:  Exp Biol Med (Maywood)       Date:  2020-09-09

Review 6.  Cutaneous Manifestations of Reactions to Biologics.

Authors:  Iris M Otani; Amy S Levin; Aleena Banerji
Journal:  Curr Allergy Asthma Rep       Date:  2018-02-21       Impact factor: 4.806

Review 7.  PRISMA--efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Man Cai Wang; Ling Yi Zhang; Wei Han; Yuan Shao; Mo Chen; Rui Ni; Gen Nian Wang; Feng Xian Wei; Ya Wu Zhang; Xiao Dong Xu; You Cheng Zhang
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

8.  Severe Henoch-Schönlein purpura with infliximab for ulcerative colitis.

Authors:  Yang Song; Yan-Hong Shi; Chong He; Chang-Qin Liu; Jun-Shan Wang; Yu-Jie Zhao; Yan-Min Guo; Rui-Jin Wu; Xiao-Yue Feng; Zhan-Ju Liu
Journal:  World J Gastroenterol       Date:  2015-05-21       Impact factor: 5.742

9.  Real-life burden of adverse reactions to biological therapy in inflammatory bowel disease: a single-centre prospective case series.

Authors:  Tiziana Larussa; Antonio Basile; Caterina Palleria; Chiara Iannelli; Ada Vero; Lidia Giubilei; Caterina De Sarro; Evelina Suraci; Raffaella Marasco; Maria Imeneo; Emilio Russo; Ludovico Abenavoli; Giovambattista De Sarro; Francesco Luzza
Journal:  Med Pharm Rep       Date:  2021-07-29

10.  Paradoxical skin lesions induced by anti-TNF-α agents in SAPHO syndrome.

Authors:  Chen Li; Xia Wu; Yihan Cao; Yueping Zeng; Weihong Zhang; Shuo Zhang; Yuehua Liu; Hongzhong Jin; Wen Zhang; Li Li
Journal:  Clin Rheumatol       Date:  2018-04-03       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.